Emmanuel Cognat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4081618/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	9.0	204
2	Abnormal recruitment of extracellular matrix proteins by excess Notch3ECD: a new pathomechanism in CADASIL. Brain, 2013, 136, 1830-1845.	7.6	167
3	<scp>CADASIL</scp> and <scp>CARASIL</scp> . Brain Pathology, 2014, 24, 525-544.	4.1	155
4	Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E796-805.	7.1	77
5	Reducing <scp>T</scp> imp3 or vitronectin ameliorates disease manifestations in <scp>CADASIL</scp> mice. Annals of Neurology, 2016, 79, 387-403.	5.3	74
6	Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1043-1046.	1.9	61
7	Cerebral Venous Thrombosis in Inflammatory Bowel Diseases: Eight Cases and Literature Review. International Journal of Stroke, 2011, 6, 487-492.	5.9	53
8	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.1	50
9	Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model. Acta Neuropathologica Communications, 2014, 2, 49.	5.2	45
10	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
11	Archetypal Arg169Cys Mutation in NOTCH3 Does Not Drive the Pathogenesis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leucoencephalopathy via a Loss-of-Function Mechanism. Stroke, 2014, 45, 842-849.	2.0	34
12	CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
13	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
14	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	1.9	17
15	Preventing Post-Lumbar Puncture Headache. Annals of Emergency Medicine, 2021, 78, 443-450.	0.6	14
16	Endovascular management of extracranial occlusions at the hyperacute phase of stroke with tandem occlusions. Journal of Neuroradiology, 2018, 45, 196-201.	1.1	13
17	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338	3.4	11
18	Intracranial Extension of Extracranial Vertebral Dissection Is Associated With an Increased Risk of Ischemic Events. Stroke, 2019, 50, 2231-2233.	2.0	10

EMMANUEL COGNAT

#	Article	IF	CITATIONS
19	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored forÂCognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
20	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
21	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	2.4	8
22	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
23	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754.	2.6	7
24	"Habit―gambling behaviour caused by ischemic lesions affecting the cognitive territories of the basal ganglia. Journal of Neurology, 2010, 257, 1628-1632.	3.6	6
25	Visibility of blood flow on optical coherence tomography angiography in a case of branch retinal artery occlusion. Journal of Ophthalmic and Vision Research, 2018, 13, 75.	1.0	5
26	Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort. Journal of Personalized Medicine, 2021, 11, 1183.	2.5	5
27	OUP accepted manuscript. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 397-398.	0.5	4
28	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	6.1	4
29	Differential diagnosis between sarcoidosis and granulomatosis with polyangiitis in a patient with leptomeningeal, cavernous sinus and pituitary lesions. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 691-692.	0.5	3
30	Elevated ALS Biomarker Levels in CSF of a FTD Patient at the Presymptomatic Stage of ALS. Alzheimer Disease and Associated Disorders, 2018, 32, 156-157.	1.3	3
31	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	2.6	3
32	Response to Letter Regarding Article, "Archetypal Arg169Cys Mutation in NOTCH3 Does Not Drive the Pathogenesis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leucoencephalopathy via a Loss-of-Function Mechanism― Stroke, 2014, 45, e129.	2.0	2
33	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer and Dementia, 2019, 15, P545.	'§.8	2
34	[P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P336.	0.8	1
35	Increased PKR level in human CADASIL brains. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 771-774.	2.8	1
36	Biomarqueurs du liquide cérébrospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1

#	Article	IF	CITATIONS
37	O3â€l 4â€06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.8	0
38	P3â€249: COMBINING MATHEMATICAL MODEL AND CATECHOLAMINE QUANTIFICATIONS TO SCREEN ALZHEIMI DISEASE FROM A SIMPLE BLOOD TEST. Alzheimer's and Dementia, 2018, 14, P1168.	ER 0.8	0
39	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.8	0
40	CSF synaptic proteins and plasmatic NFL correlate with cognitive function but reflect different brain lesionsÂ: A biomarker study. Morphologie, 2019, 103, 87.	0.9	0
41	Contribution of cerebrospinal fluid Alzheimer biomarkers to the diagnosis of Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
42	Reduction of behavioural inhibition disorders in behavioural variant frontotemporal dementia patients observed under semiâ€ecological conditions. Alzheimer's and Dementia, 2021, 17, .	0.8	0
43	Title is missing!. , 2020, 17, e1003289.		0
44	Title is missing!. , 2020, 17, e1003289.		0
45	Title is missing!. , 2020, 17, e1003289.		0
46	Title is missing!. , 2020, 17, e1003289.		0
47	Title is missing!. , 2020, 17, e1003289.		0
48	Title is missing!. , 2020, 17, e1003289.		0
49	Title is missing!. , 2020, 17, e1003289.		0
50	Grey and white matter correlates of behavioural disinhibition assessed under semi-ecological conditions in behavioural variant frontotemporal dementia Alzheimer's and Dementia, 2021, 17 Suppl 3, e053669.	0.8	0
51	A temporal classification method based on behavior time series data in patients with behavioral variant of frontotemporal dementia and apathy. Journal of Neuroscience Methods, 2022, 376, 109625.	2.5	0